Contents

Abb	orevi	ations		XV		
1.	Int	roduc	tion	1		
2.	General					
	2.1	Curre	nt directions	4		
		2.1.1	Strategic directions in biological standardization: WHO priorities	4		
		2.1.2	Blood products and related in vitro diagnostics: recent and planned			
			activities in biological standardization	5		
		2.1.3	Vaccines and biotherapeutics: recent and planned activities in biological			
			standardization	7		
	2.2	Repor	rts	9		
		2.2.1	Report from the WHO Blood Regulators Network	9		
		2.2.2	Report of the fifth meeting of WHO collaborating centres to support the			
			development of WHO biological reference preparations for in vitro			
			diagnostic devices	10		
		2.2.3	Report from the network of WHOCCs for the standardization and			
			evaluation of vaccines	12		
		2.2.4	Report of a WHO informal consultation on international standards for			
			biotherapeutic products	13		
	2.3	Feedb	pack from custodian laboratories	15		
		2.3.1	Developments and scientific issues highlighted by custodians of			
			WHO biological reference preparations	15		
	2.4		-cutting activities of other WHO committees and groups	21		
		2.4.1	Update on matters arising from the International Nonproprietary Names			
			Expert Group	21		
		2.4.2				
		0.4.0	WHO prequalified medicinal products	22		
		2.4.3	Proposal to transition from microbiological to physicochemical assays	22		
		2.4.4	for antibiotic potency testing	23		
		2.4.4	Labelling information for influenza vaccines intended for use in pregnant women	25		
		2.4.5	Influenza vaccine response during the start of a pandemic	26		
		2.4.5	initidenza vaccine response during the start of a pandemic	20		
3.	Inte	ernatio	onal Recommendations, Guidelines and other matters related	i		
	to t	he ma	nufacture and quality control of biological substances	28		
	3.1	Gener	ral	28		
		3.1.1	WHO good manufacturing practices for biological products	28		
		3.1.2	Update on the development of a candidate control material for			
			adventitious virus detection using deep sequencing	29		
	3.2	Biothe	erapeutics other than blood products	30		
		3.2.1	Regulatory assessment of approved rDNA-derived biotherapeutics	30		
	3.3		products and related substances	31		
		3.3.1	Ebola-related issues	31		
		3.3.2	Local production of blood products	32		
		3.3.3	Residual risk of virus infections caused by blood products	33		
		3.3.4	WHO general assessment tool for conducting gap analysis of national	•		
			regulatory systems for health products and technologies	34		

	3.4	In vitro	o diagnostic device reagents	35				
		3.4.1	Calibration of secondary standards for in vitro diagnostic devices	35				
		3.4.2	WHO prequalification of in vitro diagnostic devices	36				
	3.5		nes and related substances	37				
		3.5.1	Recommendations to assure the quality, safety and efficacy of recombinant human papillomavirus virus-like particle vaccines	37				
		3.5.2	Guidelines on the stability evaluation of vaccines for use under extended	31				
		0.0.2	controlled temperature conditions	38				
		3.5.3	Vaccine evaluation in public health emergencies - review of regulatory					
			pathways in selected countries	39				
		3.5.4	Development of Guidelines on the quality, safety and efficacy of					
			Ebola vaccines	40				
		3.5.5	Revision of Guidelines on the safe production and quality control of					
			inactivated poliomyelitis vaccines manufactured from wild poxviruses	41				
		3.5.6	International collaborative study to assess the utility of deep sequencing					
			in the quality control of oral poliomyelitis vaccines and inactivated poliomyelitis vaccines made from Sabin strains	42				
			ponomyenus vaccines made nom Sabin Strains	42				
4.	Inte	ernatio	onal Reference Materials - antibiotics	44				
	4.1	WHO	International Standards and Reference Reagents - antibiotics	44				
		4.1.1	Fourth WHO International Standard for streptomycin	44				
5.	Inte	ernatio	onal reference materials - biotherapeutics other than					
	blo	plood products						
	5.1	WHO I	international Standards and Reference Reagents - biotherapeutics other					
		than b	plood products	45				
		5.1.1	First WHO International Standard for tumour necrosis factor receptor					
			Fc fusion protein (etanercept)	45				
		5.1.2	First WHO Reference Panel for antibodies to erythropoietin (human)	46				
	5.2		sed new projects and updates - biotherapeutics other than blood products	47				
		5.2.1 5.2.2	Proposed First WHO International Standard for darbepoetin Proposed First WHO Reference Panel for in vitro bioassay of	47				
		5.2.2	erythropoietin (EPO)	47				
		5.2.3	Proposed First WHO international standards for pegylated-interferon-a-2a					
			and pegylated-interferon-a-2b	48				
		5.2.4	Proposed FirstWHO Reference ReagentforTGN1412-likefunctional activity	49				
		5.2.5	Proposed First WHO Reference Reagent for Pam ₃ CSK ₄	49				
		5.2.6	Proposed stability monitoring of the FirstWHO International Standard for					
			pegylated granulocyte colony-stimulating factor	50				
6.	International reference materials - blood products and							
		related substances						
	6.1	WHO I	International Standards and Reference Reagents - blood products and					
		related	d substances	51				
		6.1.1	FirstWHO Reference Reagent for anti-A and anti-B in serum and plasma					
		0.4.0	for use in haemagglutination assays	51				
		6.1.2	Fifth WHO International Standard for blood coagulation	E0				
	6.2	Propo	factor IX (concentrate) sed new projects and updates - blood products and related substances	52 53				
	0.2	6.2.1	Proposed First WHO International Standard for activated blood coagulation	55				
			factor X	53				

	6.2.2	Proposed First WHO Reference Panel for procoagulant activity of human immunoglobulin	5
	6.2.3	Proposed Fifth WHO International Standard for thromboplastin	J
	0.2.0	(human, recombinant)	5
	6.2.4	Proposed Fifth WHO International Standard for thromboplastin	
	0.2.4	(rabbit, plain)	5
			•
		nal reference materials - In vitro diagnostic	_
devi	ce rea	igents	5
7.1	WHO In	nternational Standards and Reference Reagents - in vitro diagnostic device	
	reagen	ts	Ę
	7.1.1	First WHO International Standard for JC virus DNA for NAT-based assays	į
	7.1.2	First WHO International Standard for BK virus DNA for NAT-based assays	į
	7.1.3	Fifth WHO International Standard for hepatitis C virus RNA for	
		NAT-based assays	(
	7.1.4	Fourth WHO International Standard for anti-toxoplasma gondii (human)	(
	7.1.5	Assignment of a holotranscobalamin value to the First WHO International	
		Standard for vitamin B12 and folate in human serum	(
	7.1.6	First WHO International Standard for human C-peptide	(
	7.1.7	First WHO Reference Panel for hepatitis E virus genotypes for	
		NAT-based assays	(
	7.1.8	Extension of the First WHO Repository of platelet transfusion relevant	
		bacterial strains	(
	7.1.9	First WHO Reference Reagent for Ebola virus antibodies	(
	7.1.10	First WHO reference reagents for Ebola virus RNA for NAT-based assays	
7.2	Propos	sed new projects and updates - in vitro diagnostic device reagents	
	7.2.1	Proposed Fourth WHO International Standard for hepatitis B virus DNA	
		for NAT-based assays	
	7.2.2	Proposed Fourth WHO International Standard for HIV-1 RNA for	
		NAT-based assays	
	7.2.3	Proposed First WHO International Standard for varicella zoster virus DNA	
		for NAT-based assays	
	7.2.4	Proposed First WHO International Standard for Trypanosoma cruzi DNA	
		for NAT-based assays	
	7.2.5	Proposed First WHO International Standard for Plasmodium vivax DNA	
		for NAT-based assays	
	7.2.6	Proposed First WHO International Standard for Plasmodium falciparum	
		antigens	
	7.2.7	Proposed First WHO Reference Panel for KRAS codon 12 and 13 mutations	
	7.2.8	Proposed Fourth WHO International Standard for prolactin (human)	
	7.2.9	Proposed First WHO Reference Panel for hepatitis E virus antibodies	
	7.2.10	Proposed First WHO Reference Panel for HIV-1 p24 antigen	
	7.2.11	Proposed First WHO Reference Panel for Babesia microti antibodies	
	7.2.12	Proposed First WHO Repository of red blood cell transfusion relevant	
		bacterial strains	
Inte	rnatio	nal reference materials - vaccines and related substances	
8.1	WHO I	nternational Standards and Reference Reagents - vaccines and	
	related	substances	
	8.1.1	First WHO International Standard for anti-EV71 serum (human)	

		8.1.2	First WHO international standards for meningococcal serogroups A and X	
			polysaccharide	78
		8.1.3	Third WHO International Standard for diphtheria toxoid for use in	
			flocculation test	79
	8.2	•	sed new projects and updates - vaccines and related substances	80
		8.2.1	Proposed First WHO international standards for meningococcal serogroups	
			Wand Y polysaccharide	80
		8.2.2	Proposed First WHO international standards for Vi polysaccharide	81
		8.2.3	Proposed First WHO International Standard for anti-Vi polysaccharide	0.0
		0.0.4	serum (human)	82
		8.2.4	Proposed First WHO Reference Panel for non-typhoidal salmonella	82
		8.2.5	O-antigen polysaccharides Proposed First WHO international standards for antibodies (human) to	02
		0.2.5	Salmonella enfer/ca serovarsTyphimurium (04,5 LPS) and	
			Enteritidis (09 LPS)	83
		8.2.6	Proposed First WHO International Standard for Salmonella enterica serovar	00
			Paratyphi A 02 polysaccharide	83
		8.2.7	Proposed First WHO International Standard for antibodies (human) to	
			Salmonella enterica Paratyphi A 02 polysaccharide	84
		8.2.8	Proposed First WHO Reference Panel for O-antigen polysaccharides for	
			Shigella strains	84
		8.2.9	Proposed First WHO Reference Panel for anti-Shigella O-antigen	
			polysaccharide serum (human)	85
		8.2.10	Proposed First WHO International Standard for anti-Clostridium difficile	
			serum (human)	86
Ann	ex 1			
	WHC) Recon	nmendations, Guidelines and other documents related to the	
			and quality control of biological substances used in medicine	87
			and quanty control of protogram capetaneous acca in incarento	٠.
Ann	ex 2			
	WHC	good (manufacturing practices for biological products	
	Repl	acemen	nt of Annex 1 of WHO Technical Report Series, No. 822	93
۸nn	ex 3			
AIIII		ilatory s	assessment of approved rDNA-derived biotherapeutics	
	ixegi	ilatory a	assessment of approved 1DNA-derived biotherapedities	
	Adde	endum t	o Annex 4 of WHO Technical Report Series, No. 987	131
Ann	ex 4			
	Reco	mmend	dations to assure the quality, safety and efficacy of recombinant	
	huma	an papi	llomavirus virus-like particle vaccines	
	Repl	acemen	nt of Annex 1 of WHO Technical Report Series, No. 962	147
Δnn	ex 5			
AIIII	• • • •	alinaa -	on the stability evaluation of vessions for use under system ded contactly	
			on the stability evaluation of vaccines for use under extended controlled conditions	235
Δnn	ex 6	cialuie	CONTURIORIO	233
AIIII		gical su	ubstances: WHO International Standards, Reference Reagents and	
		rence P	_	265